(Q33809965)

29 July 2017

1 reference

title

Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations (English)

1 reference

29 July 2017

1 reference

Wisløff F

1

1 reference

29 July 2017

Gulbrandsen N

series ordinal

2

1 reference

29 July 2017

Nord E

series ordinal

3

1 reference

29 July 2017

publication date

1 October 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

16

1 reference

29 July 2017

issue

4

1 reference

29 July 2017

page(s)

329-341

1 reference

Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group.

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199916040-00002

Comparison of trends in the incidence of multiple myeloma in Malmö, Sweden, and other countries, 1950-1979.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199916040-00002

Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199916040-00002

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199916040-00002

Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199916040-00002

Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199916040-00002

A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199916040-00002

Interferon-alpha for induction and maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of other studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199916040-00002

Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199916040-00002

Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199916040-00002

Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199916040-00002

Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199916040-00002

A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199916040-00002

Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199916040-00002

The economics of hypertension and stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199916040-00002

Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199916040-00002

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199916040-00002

Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199916040-00002

Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199916040-00002

Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199916040-00002

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-199916040-00002

A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study

21 January 2018

1 reference

12 December 2020

Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy

1 reference

12 December 2020

Economic impact of using clodronate in the management of patients with multiple myeloma

1 reference

12 December 2020

Has the incidence of multiple myeloma in old age been underestimated? The myeloma project of health region I in Norway. I

1 reference

12 December 2020

A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma

1 reference

12 December 2020

High-dose intravenous melphalan for plasma-cell leukaemia and myeloma

1 reference

12 December 2020

Economics of bone marrow transplantation

1 reference

12 December 2020

MRC trial of alpha2b-interferon maintenance therapy in first plateau phase of multiple myeloma

1 reference

12 December 2020

Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial.

1 reference

12 December 2020

Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial

1 reference

12 December 2020

Comparative survival, quality of life and cost-effectiveness of intensive therapy with autologous blood cell transplantation or conventional chemotherapy in multiple myeloma

1 reference

12 December 2020

The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma

1 reference

12 December 2020

Patient preferences for interferon alfa in multiple myeloma

1 reference

12 December 2020

Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study

1 reference

12 December 2020

Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation

1 reference

12 December 2020

Peripheral blood stem cell transplantation after high-dose therapy in patients with malignant lymphoma: a retrospective comparison with autologous bone marrow transplantation

1 reference

12 December 2020

Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

1 reference

12 December 2020

Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.

1 reference

12 December 2020

G-CSF post-autologous progenitor cell transplantation: a randomized study of 5, 10, and 16 micrograms/kg/day

1 reference

12 December 2020

Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation

1 reference

12 December 2020

Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens

1 reference

12 December 2020

Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

1 reference

12 December 2020

Costs of introducing autologous BMT in the treatment of lymphoma and acute leukaemia in The Netherlands

1 reference

12 December 2020

Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS

1 reference

12 December 2020

[Economic costs of autotransplantation of hematopoietic progenitors]

1 reference

12 December 2020

An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma

1 reference

12 December 2020

Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study

1 reference

12 December 2020

High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma

1 reference

12 December 2020

Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer

1 reference

12 December 2020

Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden

1 reference

12 December 2020

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group

1 reference

12 December 2020

Treatments for newly diagnosed multiple myeloma: analysis of survival data and cost-effectiveness evaluation

1 reference

12 December 2020

Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients

1 reference

12 December 2020

Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group

1 reference

12 December 2020

Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial

1 reference

12 December 2020

Intensive treatment of multiple myeloma and criteria for complete remission

1 reference

12 December 2020

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

12 December 2020

Utilities and quality-adjusted life years

1 reference

12 December 2020

Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support

1 reference

12 December 2020

Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group

1 reference

12 December 2020

Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and N

1 reference

12 December 2020

Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma

1 reference

12 December 2020

10.2165/00019053-199916040-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1019887892

0 references

Fatcat ID

release_7fvfxtbh3ze3fdio77mzjw677q

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7fvfxtbh3ze3fdio77mzjw677q

24 November 2022

mapped directly with Wikidata item

1 reference